These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31073151)

  • 1. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
    Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
    Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
    Yamazaki H; Shirakawa K; Matsumoto T; Kazuma Y; Matsui H; Horisawa Y; Stanford E; Sarca AD; Shirakawa R; Shindo K; Takaori-Kondo A
    PLoS One; 2020; 15(1):e0223463. PubMed ID: 31914134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
    Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
    Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3B is preferentially expressed at the G2/M phase of cell cycle.
    Hirabayashi S; Shirakawa K; Horisawa Y; Matsumoto T; Matsui H; Yamazaki H; Sarca AD; Kazuma Y; Nomura R; Konishi Y; Takeuchi S; Stanford E; Kawaji H; Murakawa Y; Takaori-Kondo A
    Biochem Biophys Res Commun; 2021 Mar; 546():178-184. PubMed ID: 33592502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
    Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
    Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells.
    Kazuma Y; Shirakawa K; Tashiro Y; Yamazaki H; Nomura R; Horisawa Y; Takeuchi S; Stanford E; Konishi Y; Matsui H; Matsumoto T; Tanabe F; Morishita R; Ito S; Takaori-Kondo A
    Sci Rep; 2022 Feb; 12(1):2278. PubMed ID: 35145187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
    Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
    PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
    Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
    Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
    Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
    Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
    Cescon DW; Haibe-Kains B; Mak TW
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.
    Vieira VC; Leonard B; White EA; Starrett GJ; Temiz NA; Lorenz LD; Lee D; Soares MA; Lambert PF; Howley PM; Harris RS
    mBio; 2014 Dec; 5(6):. PubMed ID: 25538195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic inhibitors of APOBEC3B-induced mutagenesis.
    Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
    Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
    Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
    Wang D; Li X; Li J; Lu Y; Zhao S; Tang X; Chen X; Li J; Zheng Y; Li S; Sun R; Yan M; Yu D; Cao G; Yang Y
    Gut; 2019 Oct; 68(10):1846-1857. PubMed ID: 31154396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
    Periyasamy M; Singh AK; Gemma C; Farzan R; Allsopp RC; Shaw JA; Charmsaz S; Young LS; Cunnea P; Coombes RC; Győrffy B; Buluwela L; Ali S
    Oncogene; 2021 Feb; 40(6):1077-1090. PubMed ID: 33323971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Papillomavirus 16 E6 Upregulates APOBEC3B via the TEAD Transcription Factor.
    Mori S; Takeuchi T; Ishii Y; Yugawa T; Kiyono T; Nishina H; Kukimoto I
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary mucosal melanomas of the head and neck are characterised by overexpression of the DNA mutating enzyme APOBEC3B.
    Argyris PP; Naumann J; Jarvis MC; Wilkinson PE; Ho DP; Islam MN; Bhattacharyya I; Gopalakrishnan R; Li F; Koutlas IG; Giubellino A; Harris RS
    Histopathology; 2023 Mar; 82(4):608-621. PubMed ID: 36416305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA cytosine and methylcytosine deamination by APOBEC3B: enhancing methylcytosine deamination by engineering APOBEC3B.
    Fu Y; Ito F; Zhang G; Fernandez B; Yang H; Chen XS
    Biochem J; 2015 Oct; 471(1):25-35. PubMed ID: 26195824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC3A is a prominent cytidine deaminase in breast cancer.
    Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
    PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.